Today: March 24, 2017, 1:08 pm

Market Report, "Indolent Lymphoma Global Clinical Trials Review, H1, 2014", published

Recently published research from GlobalData, "Indolent Lymphoma Global Clinical Trials Review, H1, 2014", is now available at Fast Market Research 2014-03-20 00:21:19
GlobalData's clinical trial report, "Indolent Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Indolent Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Indolent Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Indolent Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Full Report Details at
- ..

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

* Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
* Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
* Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Get this Report

* Understand the dynamics of a particular indication in a condensed manner
* Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
* Obtain discontinued trial listing for trials across the globe
* Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Partial Table of Contents:

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Indolent Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Indolent Lymphoma 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Indolent Lymphoma Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Indolent Lymphoma 32
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 32
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 32
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 34
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 35
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 36
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
F. Hoffmann-La Roche Ltd. 38
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 38
Gilead Sciences, Inc. 40
Clinical Trial Overview of Gilead Sciences, Inc. 40
Celgene Corporation 41
Clinical Trial Overview of Celgene Corporation 41
Teva Pharmaceutical Industries Limited 42
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 42
Cell Therapeutics, Inc. 43
Clinical Trial Overview of Cell Therapeutics, Inc. 43
GlaxoSmithKline plc 44
Clinical Trial Overview of GlaxoSmithKline plc 44
Sanofi 45
Clinical Trial Overview of Sanofi 45
Pharmacyclics, Inc. 46
Clinical Trial Overview of Pharmacyclics, Inc. 46
Infinity Pharmaceuticals, Inc. 47
Clinical Trial Overview of Infinity Pharmaceuticals, Inc. 47
Bayer AG 48
Clinical Trial Overview of Bayer AG 48
Clinical Trial Overview of Top Institutes / Government 49
National Cancer Institute 49
Clinical Trial Overview of National Cancer Institute 49
The University of Texas M. D. Anderson Cancer Center 50
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 50
Memorial Sloan Kettering Cancer Center 51

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 911 Words
Related Articles
More From Health
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo [..]
PromarkerD Predictive Diagnostics for DKD to Roll-out [..]
PERTH, AUSTRALIA, Mar 22, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader [..]
Do Prostalgene Drops Help To Restore Prostate [..]
Prostate enlargement is among the most common health problems for men over 50. With age the incidence of this condition [..]
Is OnycoSolve Spray The Key To Obliterating [..]
Toenail fungus is an undesirable but stubborn infection that comes with sweating, itching, cracking and scaling of the feet, inflammations, [..]
New Research reveals Asia poised as Preferred [..]
SYDNEY, Mar 10, 2017 - (ACN Newswire) - Frost & Sullivan has released its latest white paper, 'Asia: Preferred Destination for [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.